BiOpticROCO:6850 92 Pretax Margin % is 0.65% as of Dec. 2025, which is 96% below its 10-year median of 17.41. GuruFocus rates ROCO:6850 with a GF Score™ of 92/100 and a GF Value™ of NT$44.90 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 938 Biotechnology companies, BiOptic ranks better than 73.77% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. BiOptic's Pre-Tax Income for the
six
months ended in Dec. 2025 was NT$0.8 Mil. BiOptic's Revenue for the
six
months ended in Dec. 2025 was NT$129.0 Mil. Therefore, BiOptic's pretax margin for the quarter that ended in Dec. 2025 was 0.65%.
The historical rank and industry rank for BiOptic's Pretax Margin % or its related term are showing as below:
ROCO:6850'
s Pretax Margin % Range Over the Past 10 Years
Min: -23.99 Med: 17.41 Max: 33.84
Current: 2.51
ROCO:6850's Pretax Margin % is ranked better than 73.77% of 938
companies
in the Biotechnology industry
Industry Median: -89.895
vs ROCO:6850: 2.51
BiOptic (ROCO:6850) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
BiOptic Pretax Margin % Related Terms
BiOptic Pretax Margin % Historical Data
* Premium members only.
The historical data trend for BiOptic's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6850 vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, BiOptic's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BiOptic Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BiOptic's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where BiOptic's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BiOptic (ROCO:6850) has a Pretax Margin % of 0.65% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on BiOptic and its competitors. This is 96% below median its historical median of 17.41. According to the industry distribution chart, BiOptic ranks #246 out of 938 companies in the Biotechnology industry, placing it in the top 26.2%.
Is BiOptic's Pretax Margin % too high?
BiOptic's current Pretax Margin % of 0.65% is 96% below median its 10-year median of 17.41. Based on the distribution chart, BiOptic ranks #246 out of 938 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BiOptic has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BiOptic's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BiOptic ranks #246 out of 938 companies for Pretax Margin %. This puts BiOptic in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on BiOptic and its competitors. BiOptic's current Pretax Margin % is 0.65%, which is 96% below median its own 10-year median of 17.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BiOptic stock overvalued right now?
Based on GuruFocus' analysis, BiOptic (ROCO:6850) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$44.90, compared to a current price of NT$34.25 — trading 23.7% below its estimated fair value. The current Pretax Margin % is 0.65%, which is 96% below median its 10-year median of 17.41. BiOptic's overall GF Score™ is 92/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For BiOptic (ROCO:6850), the current Pretax Margin % is 0.65% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BiOptic (ROCO:6850) Overvalued in 2026?
Based on GuruFocus' analysis, BiOptic stock appears to be undervalued.
The current stock price of NT$34.25 is trading 23.7% below its estimated GF Value™ of NT$44.90.
GuruFocus considers BiOptic to be Modestly Undervalued.
Key valuation signals for ROCO:6850:
Pretax Margin %: 0.65% (96% below median its 10-year median of 17.41)
GF Value™: NT$44.90 vs. price of NT$34.25 (23.7% below fair value)
No single metric tells the full story. See the ROCO:6850 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BiOptic Inc is a biotechnology instrumentation company that develops scientific products for research and clinical applications. It serves professionals and laboratories dedicated to life science research, clinical diagnostics, pharmaceutical and food industries, animal husbandry, and agriculture, performing diagnostic molecular genetic analyses.
92GF Score
Get the complete analysis for ROCO:6850
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6850 has been successfully added to your 
